Annie M. Dude
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Annie M. Dude has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Lynn M. Yee
Division of Maternal—Fetal Medicine, Department of Obstetrics & Gynecology, Northwestern University Chicago, Illinois, USA
12 shared publicationsRobert M. Silver
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The University of Utah, Salt Lake City, UT
4 shared publicationsWilliam A. Grobman
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University, Columbus, OH
4 shared publications- Beth A. Plunkett
Department of Obstetrics and Gynecology, NorthShore University HealthSystem, Evanston, Illinois
3 shared publications Brian M. Mercer
Department of Obstetrics and Gynecology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH
3 shared publicationsGeorge Saade
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Medical Branch at Galveston, Galveston, TX
3 shared publications
Latest Publications
- Open Access
- 23 April 2026
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 147 (6) , 885-891
Medicaid Expansion and Severe Maternal Morbidity
OBJECTIVE: To evaluate whether there is an association between state-level Medicaid expansion and severe maternal morbidity (SMM) among Medicaid enrollees who delivered between 2010 and 2018. METHODS: This is a secondary analysis of Medicaid claims that uses national Medicaid analytic files. We included Medicaid enrollees with delivery hospitalizations between 2010 and 2018 in all states that expanded Medicaid under the Affordable Care Act (ACA) by July 2016. The primary outcome was SMM, defined using the Centers for Disease Control and Prevention's validated list of 21 indicators. The primary exposure was whether the enrollee's state of residence had expanded Medicaid 21 months before their delivery under the ACA, to allow for 1 year of expansion before a 9-month pregnancy. We also included analyses that allowed for a 9-month lag after expansion so that Medicaid expansion was in place at the start of a pregnancy. We calculated annual rates of SMM by Medicaid expansion status and analyzed trends across time. We used logistic regression to estimate the association between timing of deliveries relative to Medicaid expansion and SMM at the delivery encounter. RESULTS: Data for 6,976,586 individuals were available for analysis in 30 of the 31 states that expanded Medicaid by July 2016. Rates of SMM trended downward after Medicaid expansion in these states. Individuals who delivered at least 21 months after state Medicaid expansions were significantly less likely to experience SMM relative to those who delivered before Medicaid expansion (including blood transfusion: odds ratio [OR] 0.79; 95% CI, 0.68–0.90; excluding blood transfusion: OR 0.76; 95% CI, 0.65–0.88). CONCLUSION: Medicaid expansion was associated with decreased odds of SMM.
- 23 April 2026
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 147 (6) , 885-891
Open AccessMedicaid Expansion and Severe Maternal Morbidity
OBJECTIVE: To evaluate whether there is an association between state-level Medicaid expansion and severe maternal morbidity (SMM) among Medicaid enrollees who delivered between 2010 and 2018. METHODS: This is a secondary analysis of Medicaid claims that uses national Medicaid analytic files. We included Medicaid enrollees with delivery hospitalizations between 2010 and 2018 in all states that expanded Medicaid under the Affordable Care Act (ACA) by July 2016. The primary outcome was SMM, defined using the Centers for Disease Control and Prevention's validated list of 21 indicators. The primary exposure was whether the enrollee's state of residence had expanded Medicaid 21 months before their delivery under the ACA, to allow for 1 year of expansion before a 9-month pregnancy. We also included analyses that allowed for a 9-month lag after expansion so that Medicaid expansion was in place at the start of a pregnancy. We calculated annual rates of SMM by Medicaid expansion status and analyzed trends across time. We used logistic regression to estimate the association between timing of deliveries relative to Medicaid expansion and SMM at the delivery encounter. RESULTS: Data for 6,976,586 individuals were available for analysis in 30 of the 31 states that expanded Medicaid by July 2016. Rates of SMM trended downward after Medicaid expansion in these states. Individuals who delivered at least 21 months after state Medicaid expansions were significantly less likely to experience SMM relative to those who delivered before Medicaid expansion (including blood transfusion: odds ratio [OR] 0.79; 95% CI, 0.68–0.90; excluding blood transfusion: OR 0.76; 95% CI, 0.65–0.88). CONCLUSION: Medicaid expansion was associated with decreased odds of SMM.
- 2 April 2026
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 69 (2) , 192-195
Intrapartum Management of Diabetes and Diabetic Ketoacidosis in Pregnancy
The goal of intrapartum management of diabetes is to keep maternal blood glucose within a certain range in order to reduce the risk of maternal complications as well as decrease the risk of neonatal hypoglycemia. Several protocols are available for intrapartum management and focus on using insulin drips and glucose-containing fluids to keep maternal blood glucose within a certain range. Similarly, there are many protocols for treating diabetic ketoacidosis, all of which address volume depletion, acidosis, and electrolyte imbalances with isotonic intravenous fluids, insulin, electrolyte replacement, and treatment of the underlying cause of ketosis.
- 2 April 2026
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 69 (2) , 192-195
Intrapartum Management of Diabetes and Diabetic Ketoacidosis in Pregnancy
The goal of intrapartum management of diabetes is to keep maternal blood glucose within a certain range in order to reduce the risk of maternal complications as well as decrease the risk of neonatal hypoglycemia. Several protocols are available for intrapartum management and focus on using insulin drips and glucose-containing fluids to keep maternal blood glucose within a certain range. Similarly, there are many protocols for treating diabetic ketoacidosis, all of which address volume depletion, acidosis, and electrolyte imbalances with isotonic intravenous fluids, insulin, electrolyte replacement, and treatment of the underlying cause of ketosis.
- 4 June 2025
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 7 (8) , 101713
Unwanted pregnancies are associated with preterm birth, but not low birth weight
- 4 June 2025
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 7 (8) , 101713
Unwanted pregnancies are associated with preterm birth, but not low birth weight
- 6 May 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (9) , 1238-1239
Propranolol may Increase the Effectiveness of Oxytocin In Vitro
Linked article: This is a mini commentary on Balki et al., pp. 1228–1237 in this issue. To view this article, visit https://doi.org/10.1111/1471‐0528.18146.
- 6 May 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (9) , 1238-1239
Propranolol may Increase the Effectiveness of Oxytocin In Vitro
Linked article: This is a mini commentary on Balki et al., pp. 1228–1237 in this issue. To view this article, visit https://doi.org/10.1111/1471‐0528.18146.
- Open Access
- 2 April 2025
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 38 (1) , 2482662
The association of persistent maternal hypotension with abnormal uterine Dopplers
We aim to evaluate the association of persistent hypotension and abnormal placental hypoperfusion. We performed a secondary analysis of the Nulliparous Pregnancy Outcomes Study of patients with a singleton gestation with persistent hypotension and complete uterine artery (UtA) data. Persistent hypotension was defined as systolic blood pressure p value .017) but these findings did not persist in MVA (aOR 1.39, 95%CI 0.98, 1.95). Patients with persistent hypotension were not at an increased risk of abnormal UtA Dopplers.
- 2 April 2025
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 38 (1) , 2482662
Open AccessThe association of persistent maternal hypotension with abnormal uterine Dopplers
We aim to evaluate the association of persistent hypotension and abnormal placental hypoperfusion. We performed a secondary analysis of the Nulliparous Pregnancy Outcomes Study of patients with a singleton gestation with persistent hypotension and complete uterine artery (UtA) data. Persistent hypotension was defined as systolic blood pressure p value .017) but these findings did not persist in MVA (aOR 1.39, 95%CI 0.98, 1.95). Patients with persistent hypotension were not at an increased risk of abnormal UtA Dopplers.
- 17 March 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (7) , 916-917
Antenatal Corticosteroids and Neurodevelopmental Outcomes: Some Reassuring Data
Linked Article: This is a mini commentary on Frier et al., pp. 902–915 in this issue To view this article, visit https://doi.org/10.1111/1471‐0528.18101.
- 17 March 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 132 (7) , 916-917
Antenatal Corticosteroids and Neurodevelopmental Outcomes: Some Reassuring Data
Linked Article: This is a mini commentary on Frier et al., pp. 902–915 in this issue To view this article, visit https://doi.org/10.1111/1471‐0528.18101.
- 10 February 2025
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 43 (01) , 122-124
Ambulation during Neuraxial Analgesia in Obese Patients: A Pilot Study
Objective Prior studies have yielded mixed results regarding ambulation with neuraxial analgesia and labor outcomes, and studies did not include a significant obese population. We sought to evaluate the feasibility of ambulation with optimized neuraxial analgesia in laboring nulliparous obese patients. Study Design This was a pilot study at the University of Chicago (approval no.: IRB 19-1600, CT NCT04504682). Inclusion criteria were delivery BMI of ≥35 kg/m2, nulliparity, and term gestation. Contraindications to ambulation or vaginal delivery conferred ineligibility. Combined spinal-epidural analgesia was initiated per our institution's policy. Following epidural catheter placement, serial blood pressure measurements and motor assessments including a straight leg test and a step stool test were completed per safety protocol. Patients who passed these assessments were enrolled. Patients were encouraged to ambulate for 20 minutes every hour while on fetal and uterine telemetry. Ambulation was discouraged after complete dilation. Demographics and delivery outcomes were collected. Our primary objective was to evaluate feasibility through acceptability, and safety via the number of falls, and percentage of patients with any ambulation. The study was closed early due to enrollment difficulties and in the setting of the COVID-19 pandemic. Results A total of 105 patients were identified for the trial: 20 were ineligible for the study, 20 could not be approached, and 40 declined study participation, leaving 25 patients who consented. Of those 25, 14 completed the study. Out of 14 participants, 11 were ambulated. The average BMI of these participants was 43 kg/m2. No patients fell during the trial. Conclusion A pilot trial of ambulation during neuraxial analgesia among an obese nulliparous population demonstrated no safety concerns, but with concern regarding feasibility as there was low acceptance. Key Points These findings were presented as a poster presentation at the Central Association of Obstetrics and Gynecology meeting in Nashville, Tennessee in 2023. Received: 26 November 2024 Accepted: 13 January 2025 Article published online: 10 February 2025 © 2025. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 10 February 2025
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 43 (01) , 122-124
Ambulation during Neuraxial Analgesia in Obese Patients: A Pilot Study
Objective Prior studies have yielded mixed results regarding ambulation with neuraxial analgesia and labor outcomes, and studies did not include a significant obese population. We sought to evaluate the feasibility of ambulation with optimized neuraxial analgesia in laboring nulliparous obese patients. Study Design This was a pilot study at the University of Chicago (approval no.: IRB 19-1600, CT NCT04504682). Inclusion criteria were delivery BMI of ≥35 kg/m2, nulliparity, and term gestation. Contraindications to ambulation or vaginal delivery conferred ineligibility. Combined spinal-epidural analgesia was initiated per our institution's policy. Following epidural catheter placement, serial blood pressure measurements and motor assessments including a straight leg test and a step stool test were completed per safety protocol. Patients who passed these assessments were enrolled. Patients were encouraged to ambulate for 20 minutes every hour while on fetal and uterine telemetry. Ambulation was discouraged after complete dilation. Demographics and delivery outcomes were collected. Our primary objective was to evaluate feasibility through acceptability, and safety via the number of falls, and percentage of patients with any ambulation. The study was closed early due to enrollment difficulties and in the setting of the COVID-19 pandemic. Results A total of 105 patients were identified for the trial: 20 were ineligible for the study, 20 could not be approached, and 40 declined study participation, leaving 25 patients who consented. Of those 25, 14 completed the study. Out of 14 participants, 11 were ambulated. The average BMI of these participants was 43 kg/m2. No patients fell during the trial. Conclusion A pilot trial of ambulation during neuraxial analgesia among an obese nulliparous population demonstrated no safety concerns, but with concern regarding feasibility as there was low acceptance. Key Points These findings were presented as a poster presentation at the Central Association of Obstetrics and Gynecology meeting in Nashville, Tennessee in 2023. Received: 26 November 2024 Accepted: 13 January 2025 Article published online: 10 February 2025 © 2025. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 22 June 2023
- Published by Springer Nature in Acta Diabetologica
- Vol. 60 (10) , 1359-1363
The association between a single abnormal glucose and fetal c-peptide
Aim We aimed to evaluated if fetuses of subjects with one elevated value on the 3-h GTT had a measurable physiologic difference in fetal C-peptide levels as compared to those with no elevated values on the GTT. Methods We performed a prospective cohort study to evaluate insulin levels in singleton non-anomalous fetuses of subjects with one elevated value on the GTT as compared to subjects with no elevated values on their GTT. Fetal insulin levels were measured by fetal C-peptide in cord blood. Distribution of data was assessed and outliers representing values > the 99th and < the 1st percentiles were excluded. Data were log transformed to achieve normal distribution and univariable analyses were performed to compare fetal C-peptide levels, baseline maternal characteristics and perinatal outcomes in subjects with one elevated value as compared those with no elevated values. Results Our analysis included 99 subjects, with 49 subjects in the one elevated value group and 50 subjects in the no elevated values group. Fetal C-peptide levels (picomoles per liters, pmol/L), were significantly higher in the elevated value group as compared to the no elevated value group (mean ± SD; 4.6 ± 0.8 vs. 4.3 ± 0.7, P = 0.046, respectively). In univariable analysis, there was no significant difference in maternal characteristics or adverse composite perinatal outcomes. Conclusion Fetuses of subjects who had one elevated value on their GTT had a measurable physiologic difference in C-peptide levels as compared to fetuses of subjects with no elevated values on the GTT.
- 22 June 2023
- Published by Springer Nature in Acta Diabetologica
- Vol. 60 (10) , 1359-1363
The association between a single abnormal glucose and fetal c-peptide
Aim We aimed to evaluated if fetuses of subjects with one elevated value on the 3-h GTT had a measurable physiologic difference in fetal C-peptide levels as compared to those with no elevated values on the GTT. Methods We performed a prospective cohort study to evaluate insulin levels in singleton non-anomalous fetuses of subjects with one elevated value on the GTT as compared to subjects with no elevated values on their GTT. Fetal insulin levels were measured by fetal C-peptide in cord blood. Distribution of data was assessed and outliers representing values > the 99th and < the 1st percentiles were excluded. Data were log transformed to achieve normal distribution and univariable analyses were performed to compare fetal C-peptide levels, baseline maternal characteristics and perinatal outcomes in subjects with one elevated value as compared those with no elevated values. Results Our analysis included 99 subjects, with 49 subjects in the one elevated value group and 50 subjects in the no elevated values group. Fetal C-peptide levels (picomoles per liters, pmol/L), were significantly higher in the elevated value group as compared to the no elevated value group (mean ± SD; 4.6 ± 0.8 vs. 4.3 ± 0.7, P = 0.046, respectively). In univariable analysis, there was no significant difference in maternal characteristics or adverse composite perinatal outcomes. Conclusion Fetuses of subjects who had one elevated value on their GTT had a measurable physiologic difference in C-peptide levels as compared to fetuses of subjects with no elevated values on the GTT.
- 6 June 2023
- Published by SAGE Publications in Journal of Women's Health
- Vol. 32 (6) , 652-656
Adherence to Sexually Transmitted Infection Screening in Pregnancy
Objective: Professional guidelines and state law require screening for sexually transmitted infections (STI) during pregnancy. Our objective was to evaluate adherence to these recommendations. Methods: This is a retrospective cohort study of patients initiating prenatal care before 20 weeks' gestation. Demographic characteristics and STI screening were abstracted from prenatal records. Tests of interest included initial syphilis, human immunodeficiency virus (HIV), hepatitis B, chlamydia, and gonorrhea tests, as well as repeat (third trimester) syphilis and HIV tests. All patients were eligible for initial screening. Patients were eligible for analysis of whether they received adherent repeat third trimester screening for syphilis (mandated by state law) and HIV (institutional protocol) if they delivered at or after 32 weeks' gestation. Adherent screening was defined as performance of all recommended screening. Results: Of 2370 patients, 1816 (76.6%) received adherent initial STI screening and 181 (7.8% of 2308 patients who delivered at or after 32 weeks' gestation) received adherent repeat third trimester STI screening. After adjusting for covariates, private insurance (adjusted odds ratio [aOR] 1.45, confidence interval [95% CI] 1.12–1.95) was associated with adherent initial screening, whereas being non-Hispanic Black or Hispanic were associated with lower odds of adherent initial screening. Factors associated with adherent repeat third trimester STI screening were younger age (aOR 0.93, 95% CI 0.90–0.97) and non-Hispanic Black race (aOR 3.24, 95% CI 1.94–5.42). Those with private insurance (aOR 0.10, 95% CI 0.06–0.15) were less likely to receive adherent repeat third trimester screening. Conclusion: STI screening rates remain suboptimal. Multiple disparities exist in performance both of initial and repeat third trimester screening.
- 6 June 2023
- Published by SAGE Publications in Journal of Women's Health
- Vol. 32 (6) , 652-656
Adherence to Sexually Transmitted Infection Screening in Pregnancy
Objective: Professional guidelines and state law require screening for sexually transmitted infections (STI) during pregnancy. Our objective was to evaluate adherence to these recommendations. Methods: This is a retrospective cohort study of patients initiating prenatal care before 20 weeks' gestation. Demographic characteristics and STI screening were abstracted from prenatal records. Tests of interest included initial syphilis, human immunodeficiency virus (HIV), hepatitis B, chlamydia, and gonorrhea tests, as well as repeat (third trimester) syphilis and HIV tests. All patients were eligible for initial screening. Patients were eligible for analysis of whether they received adherent repeat third trimester screening for syphilis (mandated by state law) and HIV (institutional protocol) if they delivered at or after 32 weeks' gestation. Adherent screening was defined as performance of all recommended screening. Results: Of 2370 patients, 1816 (76.6%) received adherent initial STI screening and 181 (7.8% of 2308 patients who delivered at or after 32 weeks' gestation) received adherent repeat third trimester STI screening. After adjusting for covariates, private insurance (adjusted odds ratio [aOR] 1.45, confidence interval [95% CI] 1.12–1.95) was associated with adherent initial screening, whereas being non-Hispanic Black or Hispanic were associated with lower odds of adherent initial screening. Factors associated with adherent repeat third trimester STI screening were younger age (aOR 0.93, 95% CI 0.90–0.97) and non-Hispanic Black race (aOR 3.24, 95% CI 1.94–5.42). Those with private insurance (aOR 0.10, 95% CI 0.06–0.15) were less likely to receive adherent repeat third trimester screening. Conclusion: STI screening rates remain suboptimal. Multiple disparities exist in performance both of initial and repeat third trimester screening.
- 1 May 2023
- Published by Wolters Kluwer Health in AIDS
- Vol. 37 (6) , 999-1000
Pregnant patients living with HIV and antiretroviral therapy selection: consider the effect on gestational weight gain
- 1 May 2023
- Published by Wolters Kluwer Health in AIDS
- Vol. 37 (6) , 999-1000
Pregnant patients living with HIV and antiretroviral therapy selection: consider the effect on gestational weight gain